Company profile · Sponsor
Advanced
Advanced Accelerator Applications
- Pipeline
- 8
- Drugs
- 0
- Patents
- 0
Quick answer
Advanced (EC98C41) is a pharma company. headquartered in RUEIL-MALMAISON, FR. listed on EMA. NovaPharmaNews links 8 pipeline programs, 0 drugs, and 0 patents to this profile..
Company facts
Pipeline (8)
Search pipeline →-
RADELUMIN 2000 MBq/ml solution injectable, RADELUMIN 1300 MBq/ml solution injectable, Radelumin 2000 MBq/ml Injektionslösung, RADELUMIN 1300 MBq/ml solution injectable, Radelumin 2000 MBq/mL solución inyectable, Radelumin 2000 MBq/ml oplossing voor injectie, RADELUMIN 2000 MBq/ml solution injectable, Radelumin 1300 MBq/ml Injektionslösung, Radelumin 1300 MBq/ml oplossing voor injectie, RADELUMIN 2000 MBq/ml solution injectable, RADELUMIN 1300 MBq/ml solution injectable, Radelumin 1300 MBq/mL solución inyect
Advanced
Prostate Cancer
1 trial -
SANDOSTATIN LAR 10 mg powder and solvent for suspension for injection, LysaKare 25 g/25 g solution for infusion, SANDOSTATIN LAR 20 mg powder and solvent for suspension for injection, SANDOSTATIN LAR 30 mg powder and solvent for suspension for injection, Lutathera 370 MBq/mL solution for infusion
Advanced
Patients with somatostatin receptor positive, well-differentiated G2 and G3, advanced GEP NETs
1 trial -
Diagnóstico prick Dermatophagoides pteronyssinus, Diagnóstico prick Dermatophagoides pteronyssinus, Diagnóstico prick Dermatophagoides pteronyssinus, Diagnóstico prick control positivo, Diagnóstico prick control negativo, Diagnóstico prick Dermatophagoides pteronyssinus
Advanced
Allergies
1 trial -
Diagnóstico prick Lepidoglyphus destructor, Diagnóstico prick Lepidoglyphus destructor, Diagnóstico prick Lepidoglyphus destructor, Diagnóstico prick control negativo, Diagnóstico prick control positivo
Advanced
Allergies
1 trial -
LysaKare 25 g/25 g solution for infusion, Lutathera 370 MBq/mL solution for infusion
Advanced
somatostatin receptor positive gastroenteropancreatic neuroendocrine (GEP-NET) tumors, pheochromocytoma and paragangliomas
1 trial -
Vacuna Dermatophagoides mezcla Placebo, Vacuna Dermatophagoides mezcla 3000 TBU/ml, Test de provocación nasal, Vacuna Dermatophagoides mezcla 6000 TBU/ml, Vacuna Dermatophagoides mezcla 1000 TBU/ml
Advanced
Allergic rhinitis/rhinoconjunctivitis caused by dust mite allergy
1 trial -
[177Lu]-NeoB solution for infusion, AAA503
Advanced
Solid tumors known to overexpress GRPR and with [68Ga]-NeoB lesion uptake.
1 trial -
First-In-Human study evaluating the Safety of administration of ABD-3001 to Patients with Relapsed/Refractory Acute Myeloid Leukemia or High/Very-high Risk Myelodysplastic Syndromes
Advanced
Patients with Relapsed/Refractory Acute Myeloid Leukemia or High/Very-high Risk Myelodysplastic Syndromes, Ineligible for Intensiveor New Generation Targeted Therapy
1 trial
Frequently asked questions
What is Advanced?
Advanced (EC98C41) is a pharma company. headquartered in RUEIL-MALMAISON, FR. listed on EMA. NovaPharmaNews links 8 pipeline programs, 0 drugs, and 0 patents to this profile..
What pipeline programs does Advanced sponsor?
We track 8 ClinicalTrials.gov-linked programs for Advanced, including RADELUMIN 2000 MBq/ml solution injectable, RADELUMIN 1300 MBq/ml solution injectable, Radelumin 2000 MBq/ml Injektionslösung, RADELUMIN 1300 MBq/ml solution injectable, Radelumin 2000 MBq/mL solución inyectable, Radelumin 2000 MBq/ml oplossing voor injectie, RADELUMIN 2000 MBq/ml solution injectable, Radelumin 1300 MBq/ml Injektionslösung, Radelumin 1300 MBq/ml oplossing voor injectie, RADELUMIN 2000 MBq/ml solution injectable, RADELUMIN 1300 MBq/ml solution injectable, Radelumin 1300 MBq/mL solución inyect and 7 more. Open each program for phase, modality, NCT IDs, and indication details.
Where does Advanced company data come from?
Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.